Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, ...

Developers targeting a liver disease called nonalcoholic steatohepatitis (NASH) are among the notable outperformers in the biopharma space this year, as Madrigal Pharmaceuticals (NASDAQ ...

HepaStem is also advancing into the clinic in severe NASH. These studies mark the culmination of more than a decade of work to discover and refine liver specific cell-based therapies with ...